Article
The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations.
Scientific reports - 31 Jul 2015
Xin Shuang, Zhao Yuanyuan, Wang Xueding, Huang Yan, Zhang Jing, Guo Ying, Li Jiali, Li Hongliang, Ma Yuxiang, Chen Lingyan, Hu Zhihuang, Huang Min, Zhang Li
Abstract excerpt
Gefitinib is an essential drug for NSCLC patients harboring EGFR sensitive mutations. The approved dose 250 mg/day is based on limited clinical trials, this research aims to explore the relationship between drug exposure and gefitinib response. C trough of 87 NSCLC patients harboring EGFR sensitive mutations were determined by LC-MS/MS. The median of C trough was 173.9 ng/ml (P25-P75, 130.5-231.2 ng/ml), and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.